ParkinsonCanadaV1, Main, Exploration, bibRecord, 000C97

Perturbation of Transcription Factor Nur77 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)*

Identifieur interne : 000C97 ( Main/Exploration ); précédent : 000C96; suivant : 000C98

Perturbation of Transcription Factor Nur77 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)*

Auteurs : Matthew P. Mount ; Yi Zhang ; Mandana Amini ; Steve Callaghan ; Jerzy Kulczycki ; Zixu Mao ; Ruth S. Slack ; Hymie Anisman ; David S. Park

Source :

The Journal of Biological Chemistry [ 0021-9258 ] ; 2013.

RBID : PMC:3656291

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology), 3,4-Dihydroxyphenylacetic Acid (pharmacology), Animals, Brain (drug effects), Brain (pathology), Calpain (metabolism), Cell Death, Cyclin-Dependent Kinase 5 (metabolism), Dopaminergic Neurons (cytology), Dopaminergic Neurons (metabolism), Gene Expression Regulation, MEF2 Transcription Factors, Male, Mice, Mice, Knockout, Myogenic Regulatory Factors (metabolism), Neurotoxins (chemistry), Nuclear Receptor Subfamily 4, Group A, Member 1 (metabolism), RNA, Small Interfering (metabolism), Substantia Nigra (drug effects), Substantia Nigra (metabolism).
MESH :
- chemical , chemistry : Neurotoxins.
- chemical , metabolism : Calpain, Cyclin-Dependent Kinase 5, Myogenic Regulatory Factors, Nuclear Receptor Subfamily 4, Group A, Member 1, RNA, Small Interfering.
- chemical , pharmacology : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 3,4-Dihydroxyphenylacetic Acid.
- cytology : Dopaminergic Neurons.
- drug effects : Brain, Substantia Nigra.
- metabolism : Dopaminergic Neurons, Substantia Nigra.
- pathology : Brain.
- Animals, Cell Death, Gene Expression Regulation, MEF2 Transcription Factors, Male, Mice, Mice, Knockout.

Abstract

Background:Nur77 expression is regulated by MEF2D, which is found to be associated with the calpain-CDK5-MEF2D neuronal death pathway.

Results:Nur77 deficiency results in hypersensitivity to neuronal toxicity with Nur77 expression rescuing this loss.

Conclusion:Nur77 reduces toxic neuronal insult regulated by the calpain-CDK5-MEF2 pathway.

Significance: Previously reported calpain-CDK5-MEF2 signaling is now further elucidated with regulation of Nur77 in dopaminergic neuronal loss.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656291

DOI: 10.1074/jbc.M112.439216
PubMed: 23536182
PubMed Central: 3656291

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Perturbation of Transcription Factor <italic>Nur77</italic>
 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)<xref ref-type="fn" rid="FN1">*</xref>
</title>
<author><name sortKey="Mount, Matthew P" sort="Mount, Matthew P" uniqKey="Mount M" first="Matthew P." last="Mount">Matthew P. Mount</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Zhang, Yi" sort="Zhang, Yi" uniqKey="Zhang Y" first="Yi" last="Zhang">Yi Zhang</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Amini, Mandana" sort="Amini, Mandana" uniqKey="Amini M" first="Mandana" last="Amini">Mandana Amini</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Callaghan, Steve" sort="Callaghan, Steve" uniqKey="Callaghan S" first="Steve" last="Callaghan">Steve Callaghan</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kulczycki, Jerzy" sort="Kulczycki, Jerzy" uniqKey="Kulczycki J" first="Jerzy" last="Kulczycki">Jerzy Kulczycki</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mao, Zixu" sort="Mao, Zixu" uniqKey="Mao Z" first="Zixu" last="Mao">Zixu Mao</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Slack, Ruth S" sort="Slack, Ruth S" uniqKey="Slack R" first="Ruth S." last="Slack">Ruth S. Slack</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Anisman, Hymie" sort="Anisman, Hymie" uniqKey="Anisman H" first="Hymie" last="Anisman">Hymie Anisman</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Park, David S" sort="Park, David S" uniqKey="Park D" first="David S." last="Park">David S. Park</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23536182</idno>
<idno type="pmc">3656291</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656291</idno>
<idno type="RBID">PMC:3656291</idno>
<idno type="doi">10.1074/jbc.M112.439216</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000572</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000572</idno>
<idno type="wicri:Area/Pmc/Curation">000572</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000572</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000601</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000601</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000916</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000916</idno>
<idno type="wicri:Area/PubMed/Curation">000916</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000916</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000916</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000916</idno>
<idno type="wicri:Area/Ncbi/Merge">001419</idno>
<idno type="wicri:Area/Ncbi/Curation">001419</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001419</idno>
<idno type="wicri:doubleKey">0021-9258:2013:Mount M:perturbation:of:transcription</idno>
<idno type="wicri:Area/Main/Merge">000D06</idno>
<idno type="wicri:Area/Main/Curation">000C97</idno>
<idno type="wicri:Area/Main/Exploration">000C97</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Perturbation of Transcription Factor <italic>Nur77</italic>
 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)<xref ref-type="fn" rid="FN1">*</xref>
</title>
<author><name sortKey="Mount, Matthew P" sort="Mount, Matthew P" uniqKey="Mount M" first="Matthew P." last="Mount">Matthew P. Mount</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Zhang, Yi" sort="Zhang, Yi" uniqKey="Zhang Y" first="Yi" last="Zhang">Yi Zhang</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Amini, Mandana" sort="Amini, Mandana" uniqKey="Amini M" first="Mandana" last="Amini">Mandana Amini</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Callaghan, Steve" sort="Callaghan, Steve" uniqKey="Callaghan S" first="Steve" last="Callaghan">Steve Callaghan</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kulczycki, Jerzy" sort="Kulczycki, Jerzy" uniqKey="Kulczycki J" first="Jerzy" last="Kulczycki">Jerzy Kulczycki</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mao, Zixu" sort="Mao, Zixu" uniqKey="Mao Z" first="Zixu" last="Mao">Zixu Mao</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Slack, Ruth S" sort="Slack, Ruth S" uniqKey="Slack R" first="Ruth S." last="Slack">Ruth S. Slack</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Anisman, Hymie" sort="Anisman, Hymie" uniqKey="Anisman H" first="Hymie" last="Anisman">Hymie Anisman</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Park, David S" sort="Park, David S" uniqKey="Park D" first="David S." last="Park">David S. Park</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of Biological Chemistry</title>
<idno type="ISSN">0021-9258</idno>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology)</term>
<term>3,4-Dihydroxyphenylacetic Acid (pharmacology)</term>
<term>Animals</term>
<term>Brain (drug effects)</term>
<term>Brain (pathology)</term>
<term>Calpain (metabolism)</term>
<term>Cell Death</term>
<term>Cyclin-Dependent Kinase 5 (metabolism)</term>
<term>Dopaminergic Neurons (cytology)</term>
<term>Dopaminergic Neurons (metabolism)</term>
<term>Gene Expression Regulation</term>
<term>MEF2 Transcription Factors</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Knockout</term>
<term>Myogenic Regulatory Factors (metabolism)</term>
<term>Neurotoxins (chemistry)</term>
<term>Nuclear Receptor Subfamily 4, Group A, Member 1 (metabolism)</term>
<term>RNA, Small Interfering (metabolism)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calpain</term>
<term>Cyclin-Dependent Kinase 5</term>
<term>Myogenic Regulatory Factors</term>
<term>Nuclear Receptor Subfamily 4, Group A, Member 1</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>3,4-Dihydroxyphenylacetic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Dopaminergic Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dopaminergic Neurons</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Death</term>
<term>Gene Expression Regulation</term>
<term>MEF2 Transcription Factors</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Knockout</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><bold>Background:</bold>
<italic>Nur77</italic>
 expression is regulated by MEF2D, which is found to be associated with the calpain-CDK5-MEF2D neuronal death pathway.</p>
<p><bold>Results:</bold>
<italic>Nur77</italic>
 deficiency results in hypersensitivity to neuronal toxicity with <italic>Nur77</italic>
 expression rescuing this loss.</p>
<p><bold>Conclusion:</bold>
<italic>Nur77</italic>
 reduces toxic neuronal insult regulated by the calpain-CDK5-MEF2 pathway.</p>
<p><bold>Significance:</bold>
 Previously reported calpain-CDK5-MEF2 signaling is now further elucidated with regulation of <italic>Nur77</italic>
 in dopaminergic neuronal loss.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Amini, Mandana" sort="Amini, Mandana" uniqKey="Amini M" first="Mandana" last="Amini">Mandana Amini</name>
<name sortKey="Anisman, Hymie" sort="Anisman, Hymie" uniqKey="Anisman H" first="Hymie" last="Anisman">Hymie Anisman</name>
<name sortKey="Callaghan, Steve" sort="Callaghan, Steve" uniqKey="Callaghan S" first="Steve" last="Callaghan">Steve Callaghan</name>
<name sortKey="Kulczycki, Jerzy" sort="Kulczycki, Jerzy" uniqKey="Kulczycki J" first="Jerzy" last="Kulczycki">Jerzy Kulczycki</name>
<name sortKey="Mao, Zixu" sort="Mao, Zixu" uniqKey="Mao Z" first="Zixu" last="Mao">Zixu Mao</name>
<name sortKey="Mount, Matthew P" sort="Mount, Matthew P" uniqKey="Mount M" first="Matthew P." last="Mount">Matthew P. Mount</name>
<name sortKey="Park, David S" sort="Park, David S" uniqKey="Park D" first="David S." last="Park">David S. Park</name>
<name sortKey="Slack, Ruth S" sort="Slack, Ruth S" uniqKey="Slack R" first="Ruth S." last="Slack">Ruth S. Slack</name>
<name sortKey="Zhang, Yi" sort="Zhang, Yi" uniqKey="Zhang Y" first="Yi" last="Zhang">Yi Zhang</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C97 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C97 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3656291
   |texte=   Perturbation of Transcription Factor Nur77 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)*
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23536182" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Perturbation of Transcription Factor Nur77 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)*

Perturbation of Transcription Factor Nur77 Expression Mediated by Myocyte Enhancer Factor 2D (MEF2D) Regulates Dopaminergic Neuron Loss in Response to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)*

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.